AIMS: The cellular mechanisms underlying cardiac hypertrophy may result from changes in cardiac myocyte growth and differentiation. We tested whether sirolimus, an immunosuppressive agent that inhibits mTOR, a protein that regulates cell division and differentiation, might modify cardiac hypertrophy after cardiac transplantation. METHODS AND RESULTS: Fifty-eight cardiac transplant recipients were withdrawn from treatment with calcineurin inhibitors (CNIs) and treated with sirolimus. Eighty-three control subjects were maintained on CNIs. After 12 months, left ventricular (LV) mass decreased from 196.15 +/- 48.28 to 182.21 +/- 43.56 g (P = 0.05) and LV mass index from 99.25 +/- 20.08 to 93.82 +/- 20.22 g/m(2) (P = 0.031) in sirolimus-treated subjects but did not change in controls. The left atrial volume index of sirolimus-treated subjects decreased from 52.44 +/- 17.22 to 48.40 +/- 15.14 cc/m(2) (P = 0.008) and increased from 52.07 +/- 19.45 to 57.03 +/- 19.93 cc/m(2) (P = 0.0012) in controls. The difference between the groups was independent of blood pressure. The number of cells in myocardial biopsies positive for p27Kip1, a protein induced by mTOR inhibition, increased in sirolimus-treated subjects (P = 0.0005) and did not change in controls (P = 0.54) suggesting sirolimus acted directly on myocardium. CONCLUSION: Sirolimus may inhibit adverse ventricular remodelling resulting in cardiac hypertrophy and have potential in the treatment of conditions in which severe hypertrophy compromises cardiac function.
AIMS: The cellular mechanisms underlying cardiac hypertrophy may result from changes in cardiac myocyte growth and differentiation. We tested whether sirolimus, an immunosuppressive agent that inhibits mTOR, a protein that regulates cell division and differentiation, might modify cardiac hypertrophy after cardiac transplantation. METHODS AND RESULTS: Fifty-eight cardiac transplant recipients were withdrawn from treatment with calcineurin inhibitors (CNIs) and treated with sirolimus. Eighty-three control subjects were maintained on CNIs. After 12 months, left ventricular (LV) mass decreased from 196.15 +/- 48.28 to 182.21 +/- 43.56 g (P = 0.05) and LV mass index from 99.25 +/- 20.08 to 93.82 +/- 20.22 g/m(2) (P = 0.031) in sirolimus-treated subjects but did not change in controls. The left atrial volume index of sirolimus-treated subjects decreased from 52.44 +/- 17.22 to 48.40 +/- 15.14 cc/m(2) (P = 0.008) and increased from 52.07 +/- 19.45 to 57.03 +/- 19.93 cc/m(2) (P = 0.0012) in controls. The difference between the groups was independent of blood pressure. The number of cells in myocardial biopsies positive for p27Kip1, a protein induced by mTOR inhibition, increased in sirolimus-treated subjects (P = 0.0005) and did not change in controls (P = 0.54) suggesting sirolimus acted directly on myocardium. CONCLUSION:Sirolimus may inhibit adverse ventricular remodelling resulting in cardiac hypertrophy and have potential in the treatment of conditions in which severe hypertrophy compromises cardiac function.
Authors: T S Tsang; M E Barnes; K R Bailey; C L Leibson; S C Montgomery; Y Takemoto; P M Diamond; M A Marra; B J Gersh; D O Wiebers; G W Petty; J B Seward Journal: Mayo Clin Proc Date: 2001-05 Impact factor: 7.616
Authors: S R Ommen; R A Nishimura; C P Appleton; F A Miller; J K Oh; M M Redfield; A J Tajik Journal: Circulation Date: 2000-10-10 Impact factor: 29.690
Authors: S J Stetson; A Perez-Verdia; W Mazur; J A Farmer; M M Koerner; D G Weilbaecher; M L Entman; M A Quiñones; G P Noon; G Torre-Amione Journal: Circulation Date: 2001-08-07 Impact factor: 29.690
Authors: Giovanni Esposito; Antonio Rapacciuolo; Sathyamangla V Naga Prasad; Hideyuki Takaoka; Steven A Thomas; Walter J Koch; Howard A Rockman Journal: Circulation Date: 2002-01-01 Impact factor: 29.690
Authors: Eugenia Raichlin; Malik A Al-Omari; Courtney L Hayes; Brooks S Edwards; Robert P Frantz; Barry A Boilson; Alfredo L Clavell; Richard J Rodeheffer; John A Schirger; Sudhir S Kushwaha; Thomas G Allison; Naveen L Pereira Journal: J Heart Lung Transplant Date: 2011-05-31 Impact factor: 10.247
Authors: M Chiong; Z V Wang; Z Pedrozo; D J Cao; R Troncoso; M Ibacache; A Criollo; A Nemchenko; J A Hill; S Lavandero Journal: Cell Death Dis Date: 2011-12-22 Impact factor: 8.469